INT65964

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 1996
Last Reported 2010
Negated 2
Speculated 5
Reported most in Body
Documents 13
Total Number 19
Disease Relevance 10.10
Pain Relevance 7.54

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Adcyap1) extracellular space (Adcyap1) extracellular region (Adcyap1)
Anatomy Link Frequency
pituitary 3
spinal cord 2
brain 1
central nervous system 1
neuronal 1
Adcyap1 (Mus musculus)
Pain Link Frequency Relevance Heat
Neuropeptide 89 100.00 Very High Very High Very High
addiction 2 100.00 Very High Very High Very High
Analgesic 6 99.92 Very High Very High Very High
Pain 8 99.80 Very High Very High Very High
Morphine 24 99.12 Very High Very High Very High
analgesia 9 98.60 Very High Very High Very High
Spinal cord 25 98.52 Very High Very High Very High
Central nervous system 116 97.88 Very High Very High Very High
Dorsal horn neuron 4 97.76 Very High Very High Very High
tolerance 12 97.68 Very High Very High Very High
Disease Link Frequency Relevance Heat
Autoimmune Disease 75 99.98 Very High Very High Very High
Pain 8 99.80 Very High Very High Very High
Nociception 17 98.64 Very High Very High Very High
INFLAMMATION 95 98.24 Very High Very High Very High
Pheochromocytoma 1 97.84 Very High Very High Very High
Increased Venous Pressure Under Development 10 97.80 Very High Very High Very High
Multiple Sclerosis 140 97.36 Very High Very High Very High
Motor Neuron Diseases 70 97.08 Very High Very High Very High
Disease 115 96.92 Very High Very High Very High
Chronic Fatigue Syndrome 55 96.80 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In the final set of experiments, we sought to determine if the PACAP regulation of AMPA currents and Ca2+ transients that we described in mice were also present in the rat preparation (Fig. 5).
Spec (determine) Regulation (regulation) of PACAP
1) Confidence 0.45 Published 2006 Journal BMC Neurosci Section Body Doc Link PMC1388226 Disease Relevance 0 Pain Relevance 0.04
The effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on pain sensitivity, on morphine analgesia, on morphine tolerance and withdrawal were investigated in mice.
Spec (investigated) Regulation (effects) of PACAP in pituitary associated with pain, tolerance, withdrawal, analgesia and morphine
2) Confidence 0.45 Published 2002 Journal Regul. Pept. Section Abstract Doc Link 12409215 Disease Relevance 0.18 Pain Relevance 1.07
The effects of pituitary adenylate cyclase-activating polypeptide on acute and chronic morphine actions in mice.
Regulation (effects) of pituitary adenylate cyclase-activating polypeptide in pituitary associated with analgesic and morphine
3) Confidence 0.45 Published 2002 Journal Regul. Pept. Section Title Doc Link 12409215 Disease Relevance 0.18 Pain Relevance 1.75
The effects of pituitary adenylate cyclase-activating polypeptide (PACAP) on pain sensitivity, on morphine analgesia, on morphine tolerance and withdrawal were investigated in mice.
Spec (investigated) Regulation (effects) of pituitary adenylate cyclase-activating polypeptide in pituitary associated with pain, tolerance, withdrawal, analgesia and morphine
4) Confidence 0.45 Published 2002 Journal Regul. Pept. Section Abstract Doc Link 12409215 Disease Relevance 0.18 Pain Relevance 1.06
The aim of the present study was to evaluate the distribution of pituitary adenylate cyclase-activating polypeptide (PACAP)-like immunoreactivity in the mouse spinal cord using an antibody against PACAP38 and to determine the behavioral profile, particularly with respect to hyperalgesia, of PACAP38 given intrathecally (i.t.) in the mouse.
Regulation (distribution) of PACAP in spinal cord associated with hyperalgesia and spinal cord
5) Confidence 0.45 Published 1996 Journal Eur. J. Pharmacol. Section Abstract Doc Link 8891591 Disease Relevance 0.23 Pain Relevance 0.33
The aim of the present study was to evaluate the distribution of pituitary adenylate cyclase-activating polypeptide (PACAP)-like immunoreactivity in the mouse spinal cord using an antibody against PACAP38 and to determine the behavioral profile, particularly with respect to hyperalgesia, of PACAP38 given intrathecally (i.t.) in the mouse.
Regulation (distribution) of pituitary adenylate cyclase-activating polypeptide in spinal cord associated with hyperalgesia and spinal cord
6) Confidence 0.45 Published 1996 Journal Eur. J. Pharmacol. Section Abstract Doc Link 8891591 Disease Relevance 0.23 Pain Relevance 0.32
Next, the effects of PACAP on NMDA- and kainate-induced currents evoked in single dorsal horn neurons were studied.
Regulation (effects) of PACAP in neurons associated with dorsal horn neuron
7) Confidence 0.45 Published 2002 Journal Pain Section Abstract Doc Link 12435456 Disease Relevance 0.31 Pain Relevance 0.43
Effect of pituitary adenylate cyclase-activating polypeptide 38 (PACAP38) on tissue oxygen content--treatment in central nervous system of mice.
Regulation (Effect) of cyclase-activating polypeptide in central nervous system associated with neuropeptide and central nervous system
8) Confidence 0.39 Published 2004 Journal Regul. Pept. Section Title Doc Link 15518894 Disease Relevance 0.44 Pain Relevance 0.26
We investigated the effects of PACAP treatment, and endogenous PACAP deficiency, on infarct volume, neurological function, and the cerebrocortical transcriptional response in a mouse model of stroke, middle cerebral artery occlusion (MCAO).
Spec (investigated) Regulation (effects) of PACAP in middle cerebral artery associated with middle cerebral artery infarction and stroke
9) Confidence 0.39 Published 2006 Journal Regul. Pept. Section Abstract Doc Link 17027094 Disease Relevance 0.44 Pain Relevance 0
The mechanisms involved in the effects of PACAP on chromaffin cells have been investigated using rat pheochromocytoma PC12 cells.
Regulation (effects) of PACAP in chromaffin cells associated with pheochromocytoma
10) Confidence 0.38 Published 2002 Journal Ann. N. Y. Acad. Sci. Section Abstract Doc Link 12438165 Disease Relevance 0.18 Pain Relevance 0.23
Immunological dysregulation of vital biochemical and/or epigenetic mechanisms affecting PACAP and VIP resulting in down-regulation of cAMP are possible pathways by which disease entities become manifest.
Regulation (affecting) of PACAP associated with disease
11) Confidence 0.37 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695238 Disease Relevance 1.42 Pain Relevance 0.29
In the present study, we examined the concentration dependence of PACAP evoked changes in Ca2+ transients and PACAP enhancement of AMPA currents.
Spec (examined) Regulation (dependence) of PACAP associated with addiction
12) Confidence 0.33 Published 2006 Journal BMC Neurosci Section Body Doc Link PMC1388226 Disease Relevance 0 Pain Relevance 0.12
Unlike phase delay, phase advance elicited by a light pulse at late subjective night (5 min, CT21) was not altered in Adcyap1?
Neg (not) Regulation (altered) of Adcyap1
13) Confidence 0.24 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2823792 Disease Relevance 0 Pain Relevance 0.03
Additionally, the free-running period in DD conditions was not altered in Adcyap1?
Neg (not) Regulation (altered) of Adcyap1
14) Confidence 0.24 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2823792 Disease Relevance 0 Pain Relevance 0
Potential neuroprotective transcripts include several demonstrated to be PACAP-regulated in other contexts.
Regulation (regulated) of PACAP
15) Confidence 0.23 Published 2006 Journal Regul. Pept. Section Abstract Doc Link 17027094 Disease Relevance 0.84 Pain Relevance 0.28
The multiple functions of PACAP and VIP impact on maintaining BBB/BSB function.
Regulation (functions) of PACAP
16) Confidence 0.19 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695238 Disease Relevance 1.53 Pain Relevance 0.41
Autoimmunity affecting PACAP and VIP has been postulated as a possible contributing factor in MS and ALS,79 PD80 and CFS.81

Role of PACAP and VIP in the blood–brain/blood–spinal barrier

Regulation (affecting) of PACAP in blood associated with chronic fatigue syndrome, multiple sclerosis, autoimmune disease and motor neuron diseases
17) Confidence 0.19 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695238 Disease Relevance 1.61 Pain Relevance 0.42
Implications for the BBB/BSB functioning are important as the VRS has been identified as a location for immunoreactive lymphocytes in penetration of neuronal parenchyma.25 Also VIP has been identified in connection with neuronal function and VRS, which suggests that VIP may have a regulatory function associated with vasodilatation.26 We assert that important immunoregulation occurs in perivascular spaces and VRS and that this may involve PACAP/VIP regulation.
Regulation (regulation) of PACAP in neuronal associated with increased venous pressure under development
18) Confidence 0.19 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695238 Disease Relevance 0.75 Pain Relevance 0.07
Autoimmunity affecting PACAP and VIP has been postulated as a possible contributing factor in MS and ALS,79 PD80 and CFS.81

Role of PACAP and VIP in the blood–brain/blood–spinal barrier

Regulation (affecting) of PACAP in brain associated with chronic fatigue syndrome, multiple sclerosis, autoimmune disease and motor neuron diseases
19) Confidence 0.06 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695238 Disease Relevance 1.61 Pain Relevance 0.42

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox